Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen YHLO Biotech Co., Ltd. (688575.SS)
CNY9.53
+0.36 (+3.93%)
CN SHH Healthcare Medical - Specialties
Address
Building 1, Baolong, 2nd Road 518116
Shenzhen, GD, CN
Shenzhen, GD, CN
CEO
Yong Bo Song
Website
szyhlo.com
IPO
2021-05-17
ISIN CNE100005204
Description
Shenzhen YHLO Biotech Co., Ltd. researches, develops, produces, sells, and services in vitro diagnostic instruments and reagents in China and internationally. The company offers chemiluminescence immunoassay analyzer, diabetes solution, automated biochemical analyzer, laboratory automation, tenfly phoenix blot analyzer, VISION Pro ESR analyzer, and VISION ESR analyzer. The company was founded in 2008 and is headquartered in Shenzhen, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY9.53
+0.36 (+3.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.17
Float Shares
485.77M
Free Float %
85.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.29% | -8.36% | -25.42% | -24.93% | -30.07% | -27.46% | -30.64% | -45.53% | -77.94% | -77.47% | -77.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9.53
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.48
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-10.1% Q1'26: -4.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-92.5% Q1'26: +57.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+2.9% Q1'26: +5.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+10.2% Q1'26: +8.3% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+4.4% Q1'26: +4.4% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+5.4% Q1'26: +12.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.80× Q1'26: 7.33× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
999.01M
est: 1.31B (-23.6%)
|
1.18B
est: 1.31B (-9.9%)
|
3.98B
est: 3.97B (+0.2%)
|
2.05B
est: 1.94B (+5.9%)
|
2.01B
est: 2.00B (+0.5%)
|
1.81B
est: 1.85B (-2.3%)
|
1.96B
1.77B – 2.48B
+6.0% YoY
|
2.25B
2.20B – 2.30B
+14.7% YoY
|
2.57B
2.42B – 2.94B
+14.4% YoY
|
| EBITDA |
324.48M
est: 371.49M (-12.7%)
|
339.15M
est: 371.49M (-8.7%)
|
1.34B
est: 1.13B (+18.7%)
|
530.90M
est: 554.85M (-4.3%)
|
566.57M
est: 573.00M (-1.1%)
|
481.96M
est: 529.89M (-9.0%)
|
561.53M
507.28M – 709.73M
+6.0% YoY
|
643.97M
628.47M – 659.48M
+14.7% YoY
|
736.73M
692.91M – 840.71M
+14.4% YoY
|
| EBIT |
254.98M
est: 266.54M (-4.3%)
|
239.84M
est: 266.54M (-10.0%)
|
1.20B
est: 810.42M (+47.6%)
|
341.62M
est: 362.38M (-5.7%)
|
327.08M
est: 374.23M (-12.6%)
|
184.19M
est: 346.08M (-46.8%)
|
366.74M
331.31M – 463.54M
+6.0% YoY
|
420.59M
410.46M – 430.72M
+14.7% YoY
|
481.17M
452.55M – 549.08M
+14.4% YoY
|
| Net Income |
210.53M
est: 247.89M (-15.1%)
|
204.75M
est: 247.89M (-17.4%)
|
1.01B
est: 1.03B (-1.7%)
|
355.01M
est: 386.51M (-8.1%)
|
301.53M
est: 406.29M (-25.8%)
|
23.34M
est: 126.47M (-81.5%)
|
380.75M
113.23M – 401.46M
+201.1% YoY
|
264.21M
237.99M – 290.43M
-30.6% YoY
|
342.27M
315.81M – 405.07M
+29.5% YoY
|
| SGA |
214.71M
est: 310.33M (-30.8%)
|
293.72M
est: 310.33M (-5.4%)
|
614.15M
est: 943.57M (-34.9%)
|
558.39M
est: 408.79M (+36.6%)
|
596.75M
est: 422.16M (+41.4%)
|
148.92M
est: 390.40M (-61.9%)
|
413.71M
373.75M – 522.90M
+6.0% YoY
|
474.45M
463.03M – 485.88M
+14.7% YoY
|
542.79M
510.51M – 619.40M
+14.4% YoY
|
| EPS |
0.41
est: 0.44 (-5.9%)
|
0.38
est: 0.44 (-12.8%)
|
1.79
est: 1.81 (-1.1%)
|
0.63
est: 0.68 (-7.3%)
|
0.53
est: 0.64 (-17.5%)
|
0.04
est: 0.20 (-80.0%)
|
0.35
0.19 – 0.67
+75.0% YoY
|
0.44
0.40 – 0.48
+25.7% YoY
|
0.57
0.53 – 0.67
+29.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-126.80M
OE per share TTM
-0.24
Owner's Yield
-2.15%
Maintenance CapEx ratio
510.96%
Maint CapEx / Avg PPE
57.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 222.6K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.4K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.6K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 820.4K | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.5K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 843.3K | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 63.3K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.3K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.0K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.1K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
73.3K
Shares Outstanding
571.39M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Gen Qian | Deputy GM & Director | — | male |
| Lisheng Liao | Chief Financial Officer & Director | — | male |
| Mingyang Wang | Secretary of the Board | — | male |
| Yongbo Song | GM & Vice Chairman of the Board | — | male |
| Yujing Xiao | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688575.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
